Future of Clinical Genomics in Pediatric Oncology

Janeway, Katherine A.; Place, Andrew E.; Kieran, Mark W.; Harris, Marian H.

doi:10.1200/jco.2012.46.8470

Cited by 41 publications

(31 citation statements)

References 119 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…While hematologic malignancies comprise nearly 40% of childhood cancer [14], our results did not show a predilection for hematologic malignancies. Although not statistically significant, a slight predominance of solid tumors over hematologic malignancies was observed.…”

Section: Discussioncontrasting

confidence: 50%

Therapy-related myeloid neoplasms in children and adolescents

Cho

Choi

et al. 2016

Blood Res

View full text Add to dashboard Cite

BackgroundThis retrospective study aimed to characterize and analyze the outcome of therapy-related myeloid neoplasms (t-MNs) in children and adolescents.MethodsThe medical records of 16 patients under 21 years of age at the time of t-MN diagnosis were reviewed.ResultsThe median patient age was 11.5 years (range, 1.6–20.4 yr). Twelve patients had therapy-related acute myeloid leukemia, 3 patients had myelodysplastic syndrome, and 1 patient had chronic myelomonocytic leukemia. The median latency period was 29 months (range, 11–68 mo). Fourteen patients had cytogenetic aberrations, 8 of whom had an 11q23 abnormality. Of the 13 patients treated with curative intent, 12 patients received myeloid-type induction therapy that led to complete remission (CR) in 8 patients. Nine patients underwent allogeneic transplantation; 4 patients did not undergo transplantation due to chemotherapy-related toxic death (N=3) or parental refusal (N=1). The 5-year overall survival and event-free survival of the 13 patients treated with a curative intent were 46.2% and 30.8%, respectively. For the 9 patients who underwent allogeneic transplantation, the 5-year event-free survival was 66.7%.ConclusionA significant proportion of young patients with t-MNs can experience long-term survival, and allogeneic transplantation plays a key role for attaining cure in these patients.

show abstract

Section: Discussioncontrasting

confidence: 50%

Therapy-related myeloid neoplasms in children and adolescents

Cho

Choi

et al. 2016

Blood Res

View full text Add to dashboard Cite

show abstract

“…In addition, targeted agents are being increasingly used in pediatric cancers, and the need for individualized comprehensive genomic evaluation to identify potential molecular targets has become increasingly important 12–15 . An estimated 5% of pediatric solid tumors may harbor actionable genetic mutations, with 10% of mutations found in the germ-line 16–18 . Additionally, pharmacogenomic and pharmacodynamic studies utilize biomarkers from tumor tissue to evaluate modulation of the intended molecular targets 19 .…”

Section: Introductionmentioning

confidence: 99%

Safety and diagnostic accuracy of tumor biopsies in children with cancer

Interiano

Loh

Hinkle

et al. 2014

Cancer

View full text Add to dashboard Cite

Purpose Tumor biopsies are central to the diagnosis and management of cancer and are critical to efforts in personalized medicine and targeted therapeutics. We sought to evaluate the safety and accuracy of biopsies in children with cancer. Patients and Methods All biopsies performed in children at our institution with a suspected or established diagnosis of cancer from 2003 to 2012 were retrospectively reviewed. Patient characteristics, and disease- and procedure-related factors were correlated with procedure-related complications and diagnostic accuracy, using logistic regression analysis. Results One thousand seventy-three biopsies were performed in 808 patients. Of 1025 biopsies with adequate follow-up, 79 (7.7%) were associated with an adverse event, 35 (3.4%) of which were minor (Grade 1–2) and 32 (3.1%) were major (Grade 3–4). The most common major adverse events were blood transfusion (>10cc/kg, 24 cases) and infection requiring intravenous antibiotics (6 cases). Eleven deaths (1.4%) occurred within 30 post-procedure days but the procedure may have contributed to the outcome in only two. Nine hundred twenty-six (90.3%) biopsies provided definitive histologic diagnoses. Using multivariable analysis, biopsy site, pre-procedure hematocrit, and body mass index (BMI) were associated with risk of post-procedural complications (P<0.0001, P<0.0001, and P=0.0029, respectively). Excisional biopsy and biopsy site were independently associated with obtaining a diagnostic result (P=0.0002 and P=0.0008, respectively). Conclusion Tumor biopsies in children with cancer are associated with a low incidence of complications and a high rate of diagnostic accuracy. The predictive factors identified for adverse outcomes may aid risk assessment and pre-procedural counseling.

show abstract

“…He also referred to the role of molecular biology and its impact in diagnosis, prognosis, and the treatment of PBT, and to the necessity of identifying biologic pathways and to develop a risk stratification based on clinical and biologic prognostic factors [51, 52]. …”

Section: Session 2: Clinic Experience In Paediatric Cancermentioning

confidence: 99%

“…Apart from confirming that the drug combination was antiangiogenic, some relevant findings indicated that increased levels of CEC could be useful for detecting progression and, more importantly, the baseline levels of VEGF or the VEGF/sVEGFR-2 ratio could be useful as early predictors of response because they were significantly correlated with TTP [51]. …”

Section: Session 3: Clinical Experience In Adult Cancermentioning

confidence: 99%

Highlights from the 1st Latin American meeting on metronomic chemotherapy and drug repositioning in oncology, 27–28 May, 2016, Rosario, Argentina

Rose¹,

André²,

Rozados³

et al. 2016

ecancer

View full text Add to dashboard Cite

Following previous metronomic meetings in Marseille (2011), Milano (2014), and Mumbai (2016), the first Latin American metronomic meeting was held in the School of Medical Sciences, National University of Rosario, Rosario, Argentina on 27 and 28 of May, 2016. For the first time, clinicians and researchers with experience in the field of metronomics, coming from different countries in Latin America, had the opportunity of presenting and discussing their work. The talks were organised in three main sessions related to experience in the pre-clinical, and clinical (paediatric and adult) areas. The different presentations demonstrated that the fields of metronomic chemotherapy and repurposing drugs in oncology, known as metronomics, constitute a branch of cancer therapy in permanent evolution, which have strong groups working in LatinAmerica, both in the preclinical and the clinical settings including large, adequately designed randomised studies. It was shown that metronomics offers treatments, which, whether they are combined or not with the standard therapeutic approaches, are not only effective but also minimally toxic, with the consequent improvement of the patient’s quality of life, and inexpensive, a feature very important in low resource clinical settings. The potential use of metronomic chemotherapy was proposed as a cost/effective treatment in low-/middle-income countries, for adjuvant therapy in selected tumours. The fundamental role of the governmental agencies and non-governmental alliances, as the Metronomic Global Health Initiative, in supporting this research with public interest was underlined.

show abstract

Future of Clinical Genomics in Pediatric Oncology

Cited by 41 publications

References 119 publications

Therapy-related myeloid neoplasms in children and adolescents

Therapy-related myeloid neoplasms in children and adolescents

Safety and diagnostic accuracy of tumor biopsies in children with cancer

Highlights from the 1st Latin American meeting on metronomic chemotherapy and drug repositioning in oncology, 27–28 May, 2016, Rosario, Argentina

Contact Info

Product

Resources

About